Akeso Biopharma’s AK132 Receives Green Light for Clinical Trial in Advanced Solid Tumors
Akeso Biopharma’s (HKG: 9926) AK132, a bispecific antibody (BsAb) targeting Claudin18.2 and CD47, has received...
Cancer
Tuodao Medical’s Percutaneous Puncture Surgery Robot NP100 Approved in China
China-based surgical robot developer Tuodao Medical Technology Co., Ltd has received marketing approval for its...
Japan’s MHLW Reviews GSK’s Momelotinib for Myelofibrosis Treatment
The Ministry of Health, Labour and Welfare (MHLW) in Japan has accepted for review a...
AstraZeneca and Daiichi Sankyo Report Positive Results for Datopotamab Deruxtecan Combo in NSCLC
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced positive data from a Phase Ib...
Sichuan Kelun Pharmaceutical Secures Exclusive Rights to TBM-001 for Bone Metastasis Diagnosis
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...
Chongqing Lummy Pharmaceutical’s Subsidiary Receives NMPA Approval for CUD002 mRNA Vaccine
Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006), through its subsidiary Sichuan Cunde Therapeutics Co., Ltd,...
Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that the National Medical Products Administration...
EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer
The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...
Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China
Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...
AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC
UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...
Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...
AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial
AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...
HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...
Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial
Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...
Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial
Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...
Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...
Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening
Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...
Abbisko Therapeutics Receives EMA Approval for Phase III Study of Pimicotinib for TGCT
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...